Vistagen therapeutics stock.

Of the 54 institutional investors that purchased Vistagen Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Commodore Capital LP ($8.09M), Renaissance Technologies LLC ($4.11M), MAI Capital Management ($2.66M), State Street Corp ($2.29M), Goldman …Vistagen (NASDAQ:VTGN) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023.The primary corporate and ...Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...VistaGen Therapeutics (VTGN) In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of $30.00. The company’s shares ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 5, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Company will present …

VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) ... Common stock, $0.001 par value; 325,000,000 shares authorized at March 31, 2023 and March 31 ...

The average price target represents a 123.64% change from the last price of $3.13.Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00.... therapeutics with the potential to be faster-acting, with fewer side effects ... Social anxiety nasal spray study results make Peninsula biotech's stock shoot up ...

SOUTH SAN FRANCISCO, Calif., August 07, 2023 -- ( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to …VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...As of June 22, 2022, the Company had 206,640,955 shares of common stock outstanding. Conference Call VistaGen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update and discuss its financial results for its fiscal year 2022 ended March 31, 2022 .Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders.

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ...

The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ...

Stock Information Historical Data Press ReleasesZinger Key Points. Small-cap stocks outperformed while tech stocks lagged Friday due to a surge in U.S. Treasury yields. Gold remained above $2,000/oz, indicating renewed investor optimism, while ...Aug. 10, 2023 5:22 PM ET Vistagen Therapeutics, Inc. (VTGN) By: Deepa Sarvaiya, SA News Editor 2 Comments VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q1 GAAP EPS of -$0.94 misses by $0.08 .Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the last participant has completed the study protocol in its U.S. Phase 1 clinical trial of itruvone (PH10), the …Aug 13, 2014 · PDF Version. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014.

Analyst Recommendations on Vistagen Therapeutics, Inc. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. 2022. MT. William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform. 2022.Mar 22, 2023 · VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ... Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences. Nov 07, 2023. Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, …Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the last patient has completed the study protocol in its Phase 2 clinical trial of PH94B for the treatment of …In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco...Vistagen Therapeutics Inc. Real-Time Quotes. 3.66. BATS BZX Real-Time Price. As of 2:09pm ET. +0.28 / +8.28%. Today’s Change. 1.62. Today ||| 52-Week Range.

At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ...

VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Vistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational neuroactive pherine nasal spray in Phase 3 clinical development for acute treatment of social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed novel mechanism of action (MOA) of fasedienol is fundamentally ...The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and...The Company explicitly disclaims any obligation to update any forward-looking statements. VistaGen Company Contacts. Mark McPartland / Mark Flather. VistaGen Therapeutics. Phone: (650) 577-3606 ...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023. 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents ...Nov 10, 2022 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ...

Cerevel's stock doubled to $25.20 a share after the company put out the data in a press release. ... recently initiated coverage of VistaGen Therapeutics and pegged the company as a hidden gem.

The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 22, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) …VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... On Tuesday 10/24/2023 the closing price of the VistaGen Therapeutics Inc Registered Shs share was $3.07 on NAS. Compared to the opening price on Tuesday 10/24/2023 on NAS of $2.99, this is a gain ...Aug 7, 2023 · Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ... Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Vistagen Therapeutics Inc (VTGN) stock is trading at $4.13 as of 9:52 AM on Monday, Oct 2, a drop of -$1.11, or -21.18% from the previous closing price of $5.24. The stock has traded between $4.00 and $4.89 so far today. Volume today is light. So far 312,282 shares have traded compared to average volume of 537,046 shares.Nov 9, 2023 · MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.On average, Wall Street analysts predict that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock ...Press Releases. Year. All Years. Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results. Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific …

VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Vistagen Therapeutics is a biopharmaceutical company that develops products for anxiety, depression, and CNS disorders. The stock has a consensus rating …Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...Instagram:https://instagram. best australia forex brokernasdaq upstintermediate treasury etfradly Vistagen (NASDAQ:VTGN) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023.The primary corporate and ... are 1979 silver dollars worth anythingbac stock forcast Nov 10, 2022 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago. robloc stock The latest price target for Vistagen Therapeutics ( NASDAQ: VTGN) was reported by Stifel on Tuesday, November 14, 2023. The analyst firm set a price target for 12.00 expecting VTGN to rise to ...As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.